# US 2021/0277097 A1 · Monoclonal antibodies against the rgm a protein for use in the treatment of retinal nerve fiber layer degeneration

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0277097 A1
- Document ID: US20210277097A1
- Status: Published application
- Kind: A1
- Application number: 17/026,710
- Filed: 2020-09-21
- Published: 2021-09-09
- Earliest claimed: 2009-12-08
- Assignees: AbbVie Deutschland GmbH & Co. KG
- Applicants: AbbVie Deutschland GmbH & Co. KG
- Inventors: Bernhard K. Mueller
- Web page: https://patentgrep.com/patent/US20210277097A1

## CPC

- C07K 16/22: against growth factors {; against growth regulators}
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/02: for peripheral neuropathies
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 27/02: Ophthalmic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 16/18: against material from animals or humans
- A61K 2039/505: {comprising antibodies}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/567: Framework region [FR]
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present application describes RGM A binding proteins, particularly monoclonal antibodies, and in particular CDR grafted, humanized versions thereof, which have the ability to bind to RGM A and prevent binding of RGM proteins to RGM A receptor and other RGM A binding proteins, and therefore neutralize the function of RGM A, for use in the treatment of retinal nerve fiber layer (RNFL) degeneration as well as methods of therapeutically or prophylactically treating a mammal against RNFL degeneration.

## Claims

### Claim at position 1

-17. (canceled)

### Claim 18

A method of treating retinal nerve fiber layer (RNFL) degeneration, comprising the step of administering to a human subject in need thereof an effective amount of a composition comprising an isolated antibody, wherein the isolated antibody comprises an antigen binding domain, said antibody capable of binding an epitope of a retinal guidance molecule (RGM), said antigen binding domain comprising a heavy chain variable domain having three complementary determining regions and a light chain variable domain having three complementary determining regions, wherein the three complementary determining regions of the heavy chain variable domain have the amino acid sequence of SEQ ID NO:63, SEQ ID NO:64 and SEQ ID NO:65 and the three complementary determining regions of the light chain variable domain have the amino acid sequence of SEQ ID NO:66, SEQ ID NO:67 and SEQ ID NO:68.

### Claim 19 (depends on 18)

The method of claim 18, wherein said treatment is an therapeutic or prophylactic, neuroregenerative or neuroprotective, local or systemic treatment.

### Claim 20 (depends on 18)

The method of claim 18, wherein the antibody is a monoclonal antibody, a chimeric antibody or a humanized antibody.

### Claim 21 (depends on 18)

The method of claim 18, wherein said antibody further comprises a human acceptor framework, and wherein said human acceptor framework comprises at least one amino acid sequence selected from the group consisting of: SEQ ID NO: 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32 and 33.

### Claim 22 (depends on 21)

The method of claim 21, wherein the antibody is a monoclonal antibody, a chimeric antibody or a humanized antibody.